Monday, February 18, 2019 12:35:45 PM
There are clickable links in each post to the previous on so if you click on the link above you should be able to click back to my initial post. That first post has clickable links to all of Marker's trials which are at the end of this post.
Anytime:
1. The DoD funded trial of TPIV 110 in DCIS should begin anytime now. The funding was already secured so now we are just waiting for Mayo to start the trial. Nomura estimated sometime in 2019.
2. DoD gave Mayo a grant to fund a PII trial in TPIV 110 combined w/ Herceptin in HER2/neu positive breast cancer patients. HERE is the PR. This will be fully run by Mayo on their timeline so I don't expect it to be quick. Either way, it's fully funded.
3. IIRC we were supposed to get interim data from Tapimmune sponsored phase II trial of TPIV 200 in patients w/ TNBC. I could have completely missed it but I don't remember seeing this. I've got an email out to the company for clarification.
Q1 2019:
This is looking pretty bare from what I am seeing. Maybe a good time to add to positions if the SP dips due to lack of news barring any surprises. Presentation at ASBMT this week on February 20th and 23rd. Three oral presentations and one poster presentation. HERE is the PR with links to the abstracts. I'm not sure if we really get a bump here but this is an actual medical conference so we will get more than just a "corporate overview."
Q2 2019:
2. Completion of TPIV200 & Durvalumab combo trial w/ $AZN in patients w/ ovarian cancer. This trial had a data readout and will not continue any further.
3. Primary completion of ADSPAM trial in AML.
4. Primary completion of TACTAM trial in multiple myeloma.
5. Primary completion of STELLA trial in acute lymphoblastic leukemia.
*These are just primary completion dates. It does not mean we will 100% get any data or information. This is just the date that last participant was examined to collect final data.
2H 2019:
I’ve lumped Q3 & Q4 together as I’m going to speculate a bit since there aren’t a lot of set dates in this timeframe. Given all the completion dates in Q2 we could hear more information as to the next trials, i.e. PII & PIII trials. With the primary completion of ADSPAM, TACTAM, & STELLA I would not be surprised to see our participation at ASH. This usually takes place in the beginning of December. For those that don’t know this is a MAJOR conference, think ASCO. Obviously, speculation but I know the company is hoping to have a presentation accepted.
Interim data from Tapimmune sponsored trial of TPIV 200 in patients w/ Ovarian cancer. Should see interim data by year end 2019. This was pushed back from an initial anticipated readout in Q2
Nomura has a list of all potential upcoming events and catalysts in their research report as well. If anyone would like to read it send me your email and I will gladly send you their report.
All trials referenced above, along with the rest of Marker’s trials, are below. My first post HERE has clickable links to view all of these trials.
ADSPAM – AML: NCT02494167
TACTAL – Leukemia: NCT01333046
TACTAM – Multiple Myeloma: NCT02291848
TACTIC – Breast Cancer: NCT03093350
TACTOPS – Pancreatic Cancer: NCT03192462
STELLA – Acute Lymphoblastic Leukemia: NCT02475707
TPIV 200 for ovarian: NCT02978222
TPIV 200 for TNBC: NCT02593227
Combination trial of TPIV 200 & Durvalumab for ovarian: NCT02764333
TPIV 200 for TNBC funded by DOD w/ Mayo Clinic: NCT03012100
Good Luck everyone!
Friends don't let friends place market orders
Recent MRKR News
- Korro Announces Addition of Industry Veteran Katharine Knobil to and Resignation of David Lucchino From Its Board of Directors • GlobeNewswire Inc. • 08/28/2024 12:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/14/2024 08:47:43 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/14/2024 08:39:13 PM
- Marker Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Updates • GlobeNewswire Inc. • 08/14/2024 08:30:58 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/12/2024 11:12:59 AM
- Marker Therapeutics Awarded $2 Million Grant from NIH in Support of Phase 1 Study Investigating MT-601 in CAR-Relapsed Patients with Non-Hodgkin’s Lymphoma • GlobeNewswire Inc. • 08/12/2024 11:00:57 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 06/12/2024 08:05:47 PM
- Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend] • Edgar (US Regulatory) • 05/17/2024 10:25:14 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/15/2024 08:40:16 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/15/2024 08:03:21 PM
- Principal Investigator from City of Hope National Medical Center Invited to Present Clinical Data from Marker Therapeutics APOLLO Study at 11th Global Summit on Hematologic Malignancies • GlobeNewswire Inc. • 04/08/2024 11:00:39 AM
- Marker Therapeutics Reports Year-End 2023 Corporate and Financial Results • GlobeNewswire Inc. • 03/25/2024 09:45:00 PM
- Marker Therapeutics to Present at the H.C. Wainwright 2nd Annual Cell Therapy Virtual Conference • GlobeNewswire Inc. • 03/22/2024 04:30:51 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/01/2024 01:02:47 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/26/2024 12:58:51 PM
- Marker Therapeutics Receives Approval from United States Adopted Name (USAN) Council and International Nonproprietary Names (INN) Expert Committee for “Neldaleucel” as Nonproprietary Name for MT-601 • GlobeNewswire Inc. • 01/22/2024 12:30:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/08/2024 01:30:48 PM
- Marker Therapeutics Announces Clinical Program Updates and Pipeline Prioritization • GlobeNewswire Inc. • 01/08/2024 01:24:49 PM
- Marker Therapeutics Announces Participation in Biotech Showcase and the 19th Annual Non-Dilutive Funding Summit During “J.P. Morgan Week 2024” • GlobeNewswire Inc. • 12/21/2023 04:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/11/2023 12:35:22 PM
- Marker Therapeutics Announces Sustained Complete Response in First Lymphoma Patient Treated with MT-601 following CAR T Relapse • GlobeNewswire Inc. • 12/11/2023 12:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/20/2023 09:37:41 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/09/2023 10:03:53 PM
- Marker Therapeutics Reports Third Quarter 2023 Financial Results and Provides Business Updates • GlobeNewswire Inc. • 11/09/2023 10:00:00 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/09/2023 09:31:53 PM
VHAI - Vocodia Partners with Leading Political Super PACs to Revolutionize Fundraising Efforts • VHAI • Sep 19, 2024 11:48 AM
Dear Cashmere Group Holding Co. AKA Swifty Global Signs Binding Letter of Intent to be Acquired by Signing Day Sports • DRCR • Sep 19, 2024 10:26 AM
HealthLynked Launches Virtual Urgent Care Through Partnership with Lyric Health. • HLYK • Sep 19, 2024 8:00 AM
Element79 Gold Corp. Appoints Kevin Arias as Advisor to the Board of Directors, Strengthening Strategic Leadership • ELMGF • Sep 18, 2024 10:29 AM
Mawson Finland Limited Further Expands the Known Mineralized Zones at Rajapalot: Palokas step-out drills 7 metres @ 9.1 g/t gold & 706 ppm cobalt • MFL • Sep 17, 2024 9:02 AM
PickleJar Announces Integration With OptCulture to Deliver Holistic Fan Experiences at Venue Point of Sale • PKLE • Sep 17, 2024 8:00 AM